A phase 1b trial suggested that the oral CXCR4 inhibitor Mavorixafor, in combination with Nivolumab, exhibited potential anti-tumor activity in metastatic ccRCC patients unresponsive to Nivolumab monotherapy, particularly evident in patients with stable disease [113]. The gene discussed is CXCR4; the disease is neoplasm.